Goldman Sachs Group Inc Crinetics Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 787,028 shares of CRNX stock, worth $42.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
787,028
Previous 649,190 21.23%
Holding current value
$42.2 Million
Previous $29.1 Million 38.26%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$43.83 - $54.98 $6.04 Million - $7.58 Million
137,838 Added 21.23%
787,028 $40.2 Million
Q2 2024

Aug 13, 2024
SELL
$42.12 - $51.91 $9.05 Million - $11.2 Million
-214,917 Reduced 24.87%
649,190 $29.1 Million
Q1 2024

May 15, 2024
BUY
$34.76 - $46.81 $7.44 Million - $10 Million
213,934 Added 32.9%
864,107 $40.4 Million
Q4 2023

Feb 13, 2024
BUY
$25.62 - $37.07 $2.5 Million - $3.62 Million
97,575 Added 17.66%
650,173 $23.1 Million
Q3 2023

May 14, 2024
SELL
$15.97 - $30.59 $1.56 Million - $2.98 Million
-97,575 Reduced 15.01%
552,598 $16.4 Million
Q3 2023

Nov 14, 2023
SELL
$15.97 - $30.59 $994,100 - $1.9 Million
-62,248 Reduced 10.12%
552,598 $16.4 Million
Q2 2023

May 14, 2024
BUY
$15.73 - $23.6 $1.49 Million - $2.23 Million
94,648 Added 18.19%
614,846 $11.1 Million
Q2 2023

Aug 14, 2023
BUY
$15.73 - $23.6 $1.49 Million - $2.23 Million
94,648 Added 18.19%
614,846 $11.1 Million
Q1 2023

May 14, 2024
BUY
$15.31 - $21.1 $5.92 Million - $8.16 Million
386,882 Added 290.2%
520,198 $8.35 Million
Q1 2023

May 11, 2023
BUY
$15.31 - $21.1 $5.92 Million - $8.16 Million
386,882 Added 290.2%
520,198 $8.35 Million
Q4 2022

May 14, 2024
BUY
$15.49 - $19.05 $164,937 - $202,844
10,648 Added 8.68%
133,316 $2.44 Million
Q4 2022

Feb 13, 2023
BUY
$15.49 - $19.05 $164,937 - $202,844
10,648 Added 8.68%
133,316 $2.44 Million
Q3 2022

May 14, 2024
BUY
$18.11 - $22.37 $456,643 - $564,059
25,215 Added 25.87%
122,668 $2.41 Million
Q3 2022

Nov 10, 2022
BUY
$18.11 - $22.37 $456,643 - $564,059
25,215 Added 25.87%
122,668 $2.41 Million
Q2 2022

May 14, 2024
SELL
$16.49 - $27.64 $9.11 Million - $15.3 Million
-552,720 Reduced 85.01%
97,453 $1.82 Million
Q2 2022

Aug 15, 2022
SELL
$16.49 - $27.64 $216,843 - $363,466
-13,150 Reduced 11.89%
97,453 $1.82 Million
Q1 2022

May 16, 2022
BUY
$17.15 - $28.31 $841,773 - $1.39 Million
49,083 Added 79.78%
110,603 $2.43 Million
Q4 2021

Feb 14, 2022
BUY
$19.35 - $28.41 $117,938 - $173,158
6,095 Added 11.0%
61,520 $1.75 Million
Q3 2021

Nov 10, 2021
BUY
$16.88 - $25.23 $935,574 - $1.4 Million
55,425 New
55,425 $1.17 Million

Others Institutions Holding CRNX

# of Institutions
241
Shares Held
79.5M
Call Options Held
23.3K
Put Options Held
44.3K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.88B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email